Nasdaq

Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

Baxter International Inc. BAX recently announced the global launch of the latest version of its next-generation platform, PrisMax 2. The PrisMax 2 system aims to help streamline the delivery of ...
Nasdaq

Baxter Launches PrisMax in U.S. to Maximize Care for Critically Ill Patients

Innovative features, inspired by clinician feedback, designed to simplify treatment delivery and accuracy Straightforward connectivity to hospital EMR and unique TrueVue Analytics platform can help ...
Business Wire

Baxter Obtains U.S. FDA Emergency Use Authorizations for HF20 Set and ST Set Used in CRRT During Covid-19 Pandemic

The HF20 Set is authorized by FDA under an Emergency Use Authorization to deliver CRRT to treat patients of low weight (8-20 kg) and low blood volume who cannot tolerate a larger extracorporeal ...
Business Wire

Baxter Receives CE Mark for PrisMax, the Next-Generation System for Continuous Renal Replacement and Organ Support Therapies

Innovative features inspired by clinician feedback make delivering therapy simpler and more efficient Incorporates the latest technology to increase accuracy and performance in delivering therapy for ...